Medivation

Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan

Astellas and Medivation Announce Submission of Application for Marketing Approval of Enzalutamide, an Oral Androgen Receptor Inhibitor, in Japan

Yahoo/BusinessWire

J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizer

J&J: We're Creaming Medivation, Boehringer, Bristol And Pfizer

Forbes

Medivation Inc.: Today's Featured Drugs Laggard

Medivation Inc.: Today's Featured Drugs Laggard

The Street

Medivation

Medivation Earnings: Your Sneak Peek to the Big Announcement

Medivation Earnings: Your Sneak Peek to the Big Announcement

Wall St. Cheat Sheet

This Week in Biotech

This Week in Biotech

Motley Fool

Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation

Aragon Pharma's ARN-509 Is No Near-Term Threat to Medivation

Yahoo/Minyanville

Can Bristol-Myers Squibb Compete In Immuno-Oncology?

Can Bristol-Myers Squibb Compete In Immuno-Oncology?

Seeking Alpha

Medivation, Astellas Pharma provide update on Phase 3 PREVAIL

Medivation, Astellas Pharma provide update on Phase 3 PREVAIL

Yahoo/Fly on the Wall

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Tackling Cancer: Prostate Cancer's Biggest Current and Upcoming Players

Motley Fool